[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Beijing Shijitan Hospital, Capital Medical University\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":177},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,6,0,[8,46,70,98,125,149],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":4,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":34,"lastUpdatePostDateStruct":35,"startDateStruct":38,"completionDateStruct":40,"leadSponsor":42,"locationsCount":45},"100560314","phase-4-efficacy-and-safety-of-remimazolam-besylate-for-sedation-in-post-non-cardiac-surgery-patients-requiring-mechanical-ventilation-100560314",false,"NCT06575530","Efficacy and Safety of Remimazolam Besylate for Sedation in Post-Non-Cardiac Surgery Patients Requiring Mechanical Ventilation","Efficacy and Safety of Remimazolam Besylate for Sedation in Post-Non-Cardiac Surgery Patients Requiring Mechanical Ventilation: A Randomized Controlled Trial","Inclusion Criteria:\n\n* Aged between 18 and 64 years\n* Scheduled to undergo elective non-cardiac surgery\n* Planned for general anesthesia\n* With or without combined regional nerve blockade\n* Admitted to the ICU with endotracheal intubation post-surgery\n* With an anticipated duration of postoperative mechanical ventilation greater than 24 hours\n* Clinically requiring light sedation( target RASS score 0 to -2)\n\nExclusion Criteria:\n\n* Undergoing intracranial surgery, or having a history of severe neurological or spinal cord diseases\n* Pre-existing history of schizophrenia, epilepsy, or Parkinson's disease\n* Inability to communicate preoperatively due to coma, severe dementia, or language barriers\n* Preoperative .cardiac insufficiency or severe cardiac arrhythmias\n* Severe hepatic impariment( Child-Pugh class C)\n* Severe renal impariment\n* Preoperative( within 24 hours prior to surgery) or intraoperative administration of dexmedetomidine or remimazolam\n* Pregnancy or lactation\n* Participation in any clinical trial involving investigational drugs within 30 days prior to enrollment\n* Any other conditions deemed by the investigators to render the patient unsuitable for study participation\n* Refusal to provide written informed consent","ALL","18 Years","64 Years",{"count":20,"type":21},306,"ESTIMATED","INTERVENTIONAL",[24],"PHASE4","A multi-center, prospective, randomized, double-blind, active-controlled, no-inferiority clinical trial conducted across 5 tertiary medical centers in China. The objective of this RCT is to evaluate the sedative efficacy and safety profile of remimazolam besylate compared with dexmedetomidine in patients requiring mechanical ventilation following non-cardiac surgery. The study hypothesized that remimazolam besylate is non-inferior to dexmedetomidine regarding the primary efficacy outcome.",[27,28,29,30,31,32],"Effect of Drug","Adverse Drug Event","Mechanical Ventilation Complication","Critical Illness","Surgery","Sedation","RECRUITING","2026-06-13",{"date":36,"type":37},"2026-06-16","ACTUAL",{"date":39,"type":37},"2025-01-20",{"date":41,"type":21},"2026-06-30",{"name":43,"class":44},"Beijing Shijitan Hospital, Capital Medical University","OTHER",1,{"id":47,"slug":48,"hasResults":11,"nctId":49,"briefTitle":50,"officialTitle":51,"acronym":52,"eligibilityCriteria":53,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":54,"targetDuration":4,"studyType":56,"phases":4,"briefSummary":57,"conditions":58,"keywords":4,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":61,"lastUpdatePostDateStruct":62,"startDateStruct":64,"completionDateStruct":66,"leadSponsor":68,"locationsCount":69},"100635698","ultra-early-identification-of-futile-recanalization-after-reperfusion-therapy-in-acute-ischemic-stroke-based-on-cerebral-autoregulation-100635698","NCT07556068","Ultra-early Identification of Futile Recanalization After Reperfusion Therapy in Acute Ischemic Stroke Based on Cerebral Autoregulation","Ultra-early Identification of Futile Recanalization After Reperfusion Therapy in Acute Ischemic Stroke Based on Cerebral Autoregulation Monitoring: a Multicenter, Prospective, Observational Study","CAREFUL-CA","Inclusion Criteria:\n\n1. Age ≥ 18\n2. Clinical signs consistent with acute ischemic stroke with large vessel occlusion in the anterior circulation (intracranial segment of the internal carotid artery, middle cerebral artery M1 segment) demonstrated with CTA\u002FMRA\u002FDSA.\n3. NIHSS score ≥ 6 obtained prior to endovascular treatment.\n4. Modified Rankin Scale ≤ 1 prior to qualifying stroke.\n5. Acute ischemic stroke, undergone endovascular treatment within 24 hours of onset (time of stroke is the last known normal for wake-up stroke or with unknown onset time).with reaching the goal of mTICI grade 2b-3\n6. For patients with symptom onset within 6 hours: ASPECTS ≥ 3; for patients with symptom onset between 6 and 24 hours: age ≤ 80 years and ASPECTS ≥ 3.\n7. Patient\u002FLegally Authorized Representative has signed the Informed Consent Form.\n\nExclusion Criteria:\n\n1. Baseline CT\u002FMRI confirms the presence of multiple vascular territory acute strokes.\n2. Baseline CT\u002FMRI confirms the presence of arterial dissection.\n3. Evidence of intracranial hemorrhage or hemorrhagic transformation before thrombectomy.\n4. Known allergies or intolerances to antiplatelet agents, anticoagulation drugs, iodinated contrast and\u002For anesthetics.\n5. Severe infection (e.g. sepsis) or multiple organ failure.\n6. Known hereditary or acquired hemorrhagic diathesis or coagulation factor deficiency; oral anticoagulant therapy with INR \\> 3; or use of a factor Xa inhibitor within the preceding 48 hours with an abnormal aPTT.\n7. Baseline platelet count \\\u003C 50 × 10\\^9\u002FL.\n8. Blood glucose concentration\\\u003C50 mg\u002FdL (2.7 mmol\u002FL) or \\>400 mg\u002FdL (22.2 mmol\u002FL).\n9. Refractory hypertension that is difficult to control by medication (Defined as persistent systolic blood pressure\\>185 mmHg or diastolic blood pressure\\>110 mmHg).\n10. Severe cardiomyopathy with heart failure (LVEF ≤ 30% or NYHA class IV), acute myocardial infarction, or unstable angina.\n11. Untreated moderate or severe coronary artery stenosis, or previous coronary artery bypass surgery.\n12. Current hemodialysis or peritoneal dialysis; known severe renal insufficiency with estimated glomerular filtration rate \\\u003C 30 mL\u002Fmin or serum creatinine \\> 220 μmol\u002FL (2.5 mg\u002FdL).\n13. Known intracranial aneurysm, and cerebral arteriovenous malformation.\n14. Malignant brain tumor or CNS infection.\n15. Pre-existing neurological or psychiatric disease that would confound the neurological or functional evaluations (e.g., dementia or mental illness)\n16. Female who is pregnant or lactating at time of admission.\n17. Anticipated life expectancy \\\u003C 6 months.\n18. Current participation in another investigational drug or device study.\n19. local skin damage or other conditions that cannot cooperate with electrode sticking.\n20. severe agitation or other conditions affecting data collection.",{"count":55,"type":21},129,"OBSERVATIONAL","This multicenter, prospective, observational diagnostic accuracy study enrolls patients undergoing thrombectomy with intraoperative cerebral autoregulation monitoring and follows them up at predefined time points up to 90 days post-enrollment. The study aims to determine whether impaired cerebral autoregulation during thrombectomy can serve as an ultra-early biomarker for predicting futile recanalization in patients with acute ischemic stroke.",[59,60],"Acute Ischemic Stroke","Cerebral Autoregulation","2026-04-30",{"date":63,"type":37},"2026-05-06",{"date":65,"type":37},"2026-04-20",{"date":67,"type":21},"2026-10-20",{"name":43,"class":44},4,{"id":71,"slug":72,"hasResults":11,"nctId":73,"briefTitle":74,"officialTitle":74,"acronym":4,"eligibilityCriteria":75,"healthyVolunteers":76,"sex":16,"minAge":17,"maxAge":77,"enrollmentInfo":78,"targetDuration":4,"studyType":22,"phases":80,"briefSummary":82,"conditions":83,"keywords":88,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":90,"lastUpdatePostDateStruct":91,"startDateStruct":93,"completionDateStruct":95,"leadSponsor":97,"locationsCount":45},"100636022","evaluation-criteria-diagnostic-criteria-surgical-indications-and-establishment-of-surgical-standards-for-cerebral-tinnitus-syndrome-caused-by-internal-jugular-vein-stenosis-100636022","NCT07560280","Evaluation Criteria, Diagnostic Criteria, Surgical Indications, and Establishment of Surgical Standards for \"Cerebral Tinnitus Syndrome\" Caused by Internal Jugular Vein Stenosis.","Inclusion Criteria:\n\n1. Age between 18 and 75 years, with no gender restriction.\n2. Presence of one or more symptoms associated with \"Cerebral Tinnitus Syndrome,\" with a duration of at least 3 months.\n3. Following a detailed medical history and comprehensive physical examination, other known causes of cerebral tinnitus are preliminarily excluded, with suspected internal jugular vein stenosis (IJVS) as the cause.\n4. Imaging studies (e.g., jugular ultrasound, cervical venous CT venography (CTV)) show significant stenosis in the internal jugular vein (stenosis degree ≥50%).\n5. The patient has provided informed consent and voluntarily agrees to participate in the study, with a signed informed consent form.\n\nExclusion Criteria:\n\n1. Patients with a history of cranial surgery or diagnosed intracranial space-occupying lesions.\n2. Patients with severe cardiac, hepatic, or renal insufficiency, or other systemic diseases.\n3. Patients who have undergone any surgical or interventional procedures affecting jugular venous flow within the last 6 months.\n4. Patients with a history of psychiatric disorders or cognitive impairment who cannot complete study evaluations.\n5. Pregnant or breastfeeding women.",true,"75 Years",{"count":79,"type":21},369,[81],"NA","\"Cerebral Tinnitus,\" also known as \"cranial tinnitus,\" refers to the patient-reported perception of intracranial sounds. It often presents as \"Cerebral Tinnitus Syndrome,\" which includes symptoms such as tinnitus with hearing loss, headaches, a heavy head sensation, blurred vision, neck and shoulder discomfort, sleep disturbances, anxiety, and depression. Due to limited awareness of cerebral tinnitus, patients frequently seek treatment across multiple facilities without success, severely impacting their and their families' lives and work.\n\nXunming Ji and colleagues have pointed out that cerebral tinnitus results from stenosis of the cerebral or internal jugular veins (IJVS), which impairs cerebral venous outflow and the clearance of metabolic \"waste,\" leading to chronic metabolic damage to brain cells. Currently, studies on the diagnosis and treatment of IJVS-induced cerebral tinnitus, both domestically and internationally, are primarily case reports, lacking systematic evaluation, diagnostic, and treatment standards, which significantly impacts patient outcomes.\n\nOur project team is the first to establish evaluation criteria, diagnostic standards, surgical indications, and surgical standards for \"Cerebral Tinnitus Syndrome.\" In preliminary work, we performed internal jugular vein (IJV) decompression on 32 cerebral tinnitus patients, resulting in an IJV morphological improvement rate of 84.3%, a blood flow improvement rate of 75.0%, and a cerebral tinnitus syndrome improvement rate of 62.5%. To date, we have completed 88 IJV decompression surgeries, making ours the largest clinical center for such cases worldwide. We continue to refine these standards, notably introducing new intraoperative standards for IJV \"release\" and \"high perfusion,\".\n\nTo validate and further study these standards, this project plans to perform IJV decompression surgery on 107 cerebral tinnitus patients affected by IJVS. We aim to establish a cerebral tinnitus database and develop a cerebral tinnitus evaluation scale to standardize evaluation criteria, diagnostic standards, surgical indications, and surgical standards, ultimately advancing clinical diagnosis and treatment of Cerebral Tinnitus Syndrome",[84,85,86,87],"Jugular Vein Anomaly (Disorder)","Diagnostic Self Evaluation","Nerosurgery","Assessment, Self",[89],"Non-randomized Controlled Clinical Trial","2026-04-24",{"date":92,"type":37},"2026-05-01",{"date":94,"type":37},"2025-05-07",{"date":96,"type":21},"2030-12-30",{"name":43,"class":44},{"id":99,"slug":100,"hasResults":11,"nctId":101,"briefTitle":102,"officialTitle":103,"acronym":104,"eligibilityCriteria":105,"healthyVolunteers":76,"sex":16,"minAge":17,"maxAge":77,"enrollmentInfo":106,"targetDuration":4,"studyType":56,"phases":4,"briefSummary":108,"conditions":109,"keywords":111,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":116,"lastUpdatePostDateStruct":117,"startDateStruct":119,"completionDateStruct":121,"leadSponsor":123,"locationsCount":124},"100616885","raman-spectroscopy-based-non-invasive-blood-glucose-detection-100616885","NCT07311421","Raman Spectroscopy-Based Non-Invasive Blood Glucose Detection","Clinical Study of Non-invasive Blood Glucose Detection Technology Based on Raman Spectroscopy","Raman Glucose","Inclusion Criteria:\n\nAge range: 18-75 years old. Gender: unlimited. Health status: patients with diagnosed diabetes or healthy volunteers. Nail health status: no obvious infection, discoloration, peeling and other lesions of the nail, so as to ensure the accuracy of Raman spectroscopy measurement.\n\nWilling to participate in the study and sign the informed consent.\n\nExclusion Criteria:\n\nNail diseases: such as fungal infections, psoriasis, trauma resulting in nail damage or deformity.\n\nThe presence of factors that influenced the measurement results: Participants who used nail polish, fake nails, or nail products. Recent use of drugs containing heavy metals (which may affect nail composition) and skin conditions are not appropriate for such tests.\n\nPregnant or lactating women. People with serious chronic diseases (such as terminal cancer, end-stage renal disease) or mental illness.\n\nNon-cooperation or inability to complete the entire research process, such as refusal or inability to complete Raman spectrum acquisition.",{"count":107,"type":21},49,"Diabetes is a chronic metabolic disease that is widely prevalent globally, with its incidence rate continuously increasing, posing significant challenges to patient health and public health systems. In China, the number of diabetes patients ranks first in the world, with an adult prevalence rate as high as 12.8%. The core of diabetes management is blood glucose control. However, traditional finger-prick blood testing methods are inconvenient and have low patient compliance. In recent years, non-invasive blood glucose detection technologies have become a research hotspot. Among them, optical methods, especially spectroscopy techniques, are considered to have the most application potential due to their non-invasive, convenient, and stable characteristics.\n\nRaman spectroscopy, as an important branch of spectroscopy, has advantages such as non-invasiveness and high specificity, and has been successfully applied to blood glucose detection in laboratory settings. However, its clinical application is still in the exploratory stage. Foreign research has validated its feasibility, and domestic research has also made certain progress, but overall, it is still in its infancy. This study aims to compare the consistency and accuracy of Raman spectroscopy non-invasive blood glucose detection with traditional finger-prick blood glucose detection by comparing the blood glucose values measured by the two methods at the same time point. Additionally, the study will assess the participants' satisfaction and acceptance of the two methods through questionnaires. The results of this study will provide a scientific basis for the clinical application of Raman spectroscopy technology and offer references for the promotion of non-invasive blood glucose detection technologies. This will help advance the development of non-invasive blood glucose detection technologies and improve the treatment compliance and quality of life of diabetes patients.",[110],"Diabetes",[112,113,114,115],"Diabetes Management","Raman Spectroscopy","Non-invasive Blood Glucose Detection","Clinical Application","2025-12-26",{"date":118,"type":37},"2025-12-31",{"date":120,"type":21},"2026-01-01",{"date":122,"type":21},"2026-10-31",{"name":43,"class":44},2,{"id":126,"slug":127,"hasResults":11,"nctId":128,"briefTitle":129,"officialTitle":130,"acronym":131,"eligibilityCriteria":132,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":133,"enrollmentInfo":134,"targetDuration":4,"studyType":22,"phases":136,"briefSummary":137,"conditions":138,"keywords":4,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":140,"lastUpdatePostDateStruct":141,"startDateStruct":143,"completionDateStruct":145,"leadSponsor":147,"locationsCount":148},"100553387","safety-and-efficacy-of-selective-intra-arterial-cooling-infusion-combined-with-evt-in-acute-ischemic-stroke-100553387","NCT06485427","Safety and Efficacy of Selective Intra-Arterial Cooling Infusion Combined With EVT in Acute Ischemic Stroke","Safety and Efficacy of Selective Intra-Arterial Cooling Infusion Combined With Endovascular Thrombectomy in Acute Ischemic Stroke: A Multicenter, Randomized Controlled, Subject- and Assessor-Blind Clinical Trials","FOCUS","Inclusion Criteria\n\n1. Age ≥ 18 and ≤ 80.\n2. Clinical signs consistent with acute ischemic stroke with large vessel occlusion in the anterior circulation (intracranial segment of the internal carotid artery, middle cerebral artery M1 segment) demonstrated with CTA\u002FMRA\u002FDSA.\n3. NIHSS score obtained prior to randomization ≥ 6 and ≤ 25.\n4. Modified Rankin Scale ≤ 1 prior to qualifying stroke.\n5. Arterial puncture performed within 24 hours from symptom onset or LKW.\n6. For the patients with symptom onset within 6 hours, the ASPECT score ≥ 6; for the patients with onset within 6-24 hours, the therapy should meet the imaging criteria of DAWN or DEFUSE-3 trial.\n7. Patient\u002FLegally Authorized Representative has signed the Informed Consent Form.\n\nExclusion Criteria\n\n1. Baseline CT\u002FMRI confirms the presence of multiple vascular territory acute strokes.\n2. Baseline CT\u002FMRI confirms the presence of arterial dissection.\n3. Evidence of intracranial hemorrhage or hemorrhagic transformation before thrombectomy.\n4. Known allergies or intolerances to antiplatelet agents, anticoagulation drugs, iodinated contrast and\u002For anesthetics.\n5. Severe infection (e.g. sepsis) or multiple organ failure.\n6. Known hereditary or acquired hemorrhagic diathesis, coagulation factor deficiency; recent oral anticoagulant therapy with INR \\> 3. Patients on factor Xa inhibitor for 48 hours ago must have a normal APTT.\n7. Baseline platelet count \\\u003C 50 × 10\\^9\u002FL.\n8. Blood glucose concentration\\\u003C50 mg\u002FdL (2.7 mmol\u002FL) or \\>400 mg\u002FdL (22.2 mmol\u002FL).\n9. Refractory hypertension that is difficult to control by medication (Defined as persistent systolic blood pressure\\>185 mmHg or diastolic blood pressure\\>110 mmHg).\n10. Previous NHYA\\>1.\n11. Untreated moderate or severe coronary artery stenosis, or previous coronary artery bypass surgery.\n12. Undergoing hemodialysis or peritoneal dialysis; known severe renal insufficiency with glomerular filtration rate \\\u003C 30 mL\u002Fmin or serum creatinine \\>220 mmol\u002FL (2.5 mg\u002FdL).\n13. Known intracranial aneurysm, and cerebral arteriovenous malformation.\n14. Malignant brain tumor or CNS infection.\n15. Pre-existing neurological or psychiatric disease that would confound the neurological or functional evaluations (e.g., dementia or mental illness)\n16. Female who is pregnant or lactating at time of admission.\n17. Anticipated life expectancy \\\u003C 6 months.\n18. Current participation in another investigational drug or device study.\n19. For other reasons, the responsible clinicians believe that the patient is not suitable for continued treatment.","80 Years",{"count":135,"type":21},258,[81],"This is a multicenter, randomized, controlled, subject- and assessor-blinded clinical trial. The research objective is to evaluate the safety and efficacy of selective intra-arterial cooling infusion combined with endovascular therapy in the treatment of acute anterior circulation large vessel occlusion stroke. This trial aims to enroll 258 subjects. Patients assigned to the control group will receive best medical management (BMM) and endovascular therapy (EVT). Those in the selective intra-arterial cooling infusion group (IA-SCI group) will undergo selective intra-arterial cold saline infusion, in addition to BMM and EVT. Subjects will be interviewed face-to-face at randomization, 24±6 hours, 48±6 hours after randomization, 7±2 days\u002Fdischarge. Telephone interviews\u002F face-to face interviews will be performed at 30±3 days and 90±7 days after randomization. The primary outcome is the distribution of Modified Rankin Score at 90±7days after randomization.",[59,139],"Hypothermia","2025-04-02",{"date":142,"type":37},"2025-04-04",{"date":144,"type":37},"2024-07-03",{"date":146,"type":21},"2026-08-01",{"name":43,"class":44},9,{"id":150,"slug":151,"hasResults":11,"nctId":152,"briefTitle":153,"officialTitle":153,"acronym":4,"eligibilityCriteria":154,"healthyVolunteers":11,"sex":155,"minAge":4,"maxAge":4,"enrollmentInfo":156,"targetDuration":4,"studyType":22,"phases":158,"briefSummary":159,"conditions":160,"keywords":162,"overallStatus":168,"whyStopped":4,"lastUpdateSubmitDate":169,"lastUpdatePostDateStruct":170,"startDateStruct":172,"completionDateStruct":174,"leadSponsor":176,"locationsCount":4},"100570120","establishment-and-clinical-application-of-ai-based-multimodal-diagnosis-system-for-ovarian-tumors-100570120","NCT06703112","Establishment and Clinical Application of AI-based Multimodal Diagnosis System for Ovarian Tumors","Inclusion Criteria:\n\n* 1\\. Continuous cases admitted for diagnosis of ovarian tumor and preparation for surgical treatment;\n* 2\\. Complete imaging data (ultrasound or MRI) and tumor marker results within 3 months before surgery;\n* 3\\. Voluntarily sign informed consent.\n\nExclusion Criteria:\n\n* 1\\. Patients with non-ovarian origin tumor as surgical pathology;\n* 2\\. Repetitive cases;\n* 3\\. Cases receiving radiotherapy and chemotherapy;\n* 4\\. Recurrent cases; 5. Poor image quality of ovarian lesions;","FEMALE",{"count":157,"type":21},584,[81],"Ovarian tumors are a common disease that threatens women's health. They are insidious in onset, have over ten pathological types, and exhibit diverse biological behaviors, making accurate diagnosis a key factor in clinical decision-making and improving prognosis. Introducing AI technology to establish an auxiliary diagnosis system composed of multi-dimensional clinical data, including medical imaging and tumor markers, will greatly enhance diagnosis efficiency by predicting the pathological types of common ovarian tumors.\n\nOur research group has innovatively developed an AI-based ultrasound intelligent auxiliary diagnosis software for ovarian tumors, which has been clinically validated to be effective. This project will build on this by: (1) utilizing a wealth of multi-center retrospective clinical data to combine ultrasound, MRI images, physiological, pathological, and laboratory data to form the first multi-modal ovarian tumor public dataset supporting AI tasks; (2) using convolutional neural network technology to realize multi-modal image multi-classification intelligent recognition on this dataset based on surgical pathology as the standard, and then fuse features at the level of clinical data with the intelligent recognition model to train and validate an auxiliary diagnosis model for predicting the top ten pathological types of ovarian tumors; (3) applying privacy computing and federated learning methods to conduct multi-center, prospective validation and optimization of the above model, ultimately forming a clinical auxiliary diagnosis system that can predict the pathological types of most ovarian tumors and apply it to clinical practice.",[161],"Ovarian Tumors",[163,164,165,166,167],"Ovarian Neoplasms","Artificial Intelligence","Multimodal Imaging","Computer-Assisted Diagnosis","Privacy Computing","NOT_YET_RECRUITING","2024-11-20",{"date":171,"type":37},"2024-11-25",{"date":173,"type":21},"2025-06-01",{"date":175,"type":21},"2026-12-31",{"name":43,"class":44},""]